Print this page    •   Back to Web version of article

CAESER Study Completed

September 1996

CAESER (an acronym based on the participating sites: Canada, Australia, Europe, and South Africa) is a clinical trial comparing multiple nucleoside analogues and loviride, a non-nucleoside reverse transcriptase inhibitor, in 1,892 patients with advanced HIV infection. Initiated in March 1995 and scheduled to end in March 1997, CAESER was prematurely discontinued based on recommendations from the July 25, 1996 meeting of the Data and Safety Monitoring Board.

Entry criteria were a CD4 cell count of 25-250/mm3. Patients were receiving AZT, AZT + ddI, or AZT + ddC and were randomized to the following additional agents: 1) 3TC, 2) 3TC + loviride, or 3) placebo.

End points in the study were standard clinical criteria: an AIDS-defining opportunistic infection or tumor or death. Results of the study are outlined below.

These results indicate that 3TC added to AZT-containing anti-retroviral regimens is associated with a favorable clinical outcome.




This article was provided by Johns Hopkins AIDS Service. It is a part of the publication Hopkins HIV Report. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/art42885.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.